Dr. Karine Chevrie Profile

Dr. Karine Chevrie

at Pixium Vision

SPIE Involvement:

Author

Publications (1)

This will count as one of your downloads.

You will have access to both the presentation and article (if available).

DOWNLOAD NOW

This content is available for download via your institution's subscription. To access this item, please sign in to your personal account.

Email or Username Forgot your username?

Password Forgot your password?

Show

Keep me signed in

No SPIE account? Create an account

Proceedings Article | 21 February 2020 Presentation + Paper

Navigating the regulatory pathway for an innovative bionic vision system

K. Chevrie

Proceedings Volume 11229, 112290X (2020) https://doi.org/10.1117/12.2560182

KEYWORDS: Medical devices, Manufacturing, Clinical trials, Biomimetics, Medical device development, IRIS Consortium, Visualization, Safety, Quality systems

Read Abstract +

Bionic vision restoration systems incorporating an implantable device belong to the highest regulatory risk class in the USA and Europe (i.e Class III). As such, their release to the market or their use in clinical trials is subject to authorization by the competent authorities. These authorizations are based on thorough evaluation procedures which impose on the manufacturer the highest level of evidence of compliance with regulatory requirements. In order to obtain these authorizations in the shortest possible time, it is necessary to understand, in detail, the requirements specified in the regulations and their interpretation by the competent authorities. The means of demonstration of conformity and the criteria for acceptance must also be defined to ensure that they meet the expectations of the competent authorities. In the case of breakthrough innovation, these different aspects are even more difficult to determine as there is no predicate or state of the art on which the manufacturer and the competent authorities can rely. It is therefore necessary to deploy a regulatory strategy very early on incorporating as much input as possible from the competent authorities, in order to increase the probability of approval and thus streamline the regulatory pathway. We will present, as an example, the method we developed for the Prima Bionic Vision System and discuss the specificities of medical devices; including incremental development and short development cycles versus regulatory time and how to manage this particularity for breakthrough devices.

My Library

You currently do not have any folders to save your paper to! Create a new folder below.

Folder Name

Folder Description

View contact details

UPDATE YOUR PROFILE

Is this your profile? Update it now.

Sign into your SPIE.org account

Don’t have a profile and want one?

Create an account on SPIE.org

Access to the requested content is limited to institutions that have purchased or subscribe to SPIE eBooks. You are receiving this notice because your organization may not have SPIE eBooks access.*

*Shibboleth/Open Athens users─please sign in to access your institution's subscriptions.

To obtain this item, you may purchase the complete book in print or electronic format on SPIE.org.

ORGANIZATIONAL
Sign in with credentials provided by your organization.

Organizational Username

Organizational Password

Show/Hide Password

INSTITUTIONAL
Select your institution to access the SPIE Digital Library.

SELECT YOUR INSTITUTION

PERSONAL
Sign in with your SPIE account to access your personal subscriptions or to use specific features such as save to my library, sign up for alerts, save searches, etc.

PERSONAL SIGN IN

No SPIE Account? Create one

PURCHASE THIS CONTENT

SUBSCRIBE TO DIGITAL LIBRARY

50 downloads per 1-year subscription

Members: $195

Non-members: $335 ADD TO CART

25 downloads per 1 - year subscription

Members: $145

Non-members: $250 ADD TO CART

PURCHASE SINGLE ARTICLE

Includes PDF, HTML & Video, when available

Members:

Non-members: ADD TO CART

Keywords/Phrases

Search In:

Publication Years